Clinical trials: Metastatic Castration-Resistant Prostate Cancer
Castration-resistant Prostate Cancer, Metastatic Cancer
Predictive Nomogram of CRPC
This is an observational, prospective (study following participants forward in time), multi-center (study conducted in more than 1 center) study to identify the risk factors, then develop and validate the predictive Nomogram of…
- Trial name
- CRPC-PN (NCT03177551)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University Second Hospital
Metastatic Castration-resistant Prostate Cancer
Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)
This phase I clinical trial is to evaluate the safety of Prodencel (an autologous dendritic cell therapeutic tumor vaccine.) in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT05533203
- Testing
- Prodencel; an autologous dendritic cell therapeutic tumor vaccine
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Humantech Biotechnology Co. Ltd
Metastatic Castration-resistant Prostate Cancer
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
- Trial name
- NCT06067841
- Testing
- BMS-986460
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 140 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
RATIONALE: Drugs used in chemotherapy, such as carboplatin and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01051570
- Testing
- carboplatin, RAD 001, prednisone
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
The goal of this clinical trial is to find out if taking natural products green tea and quercetin along with docetaxel chemotherapy improves the therapy of advanced prostate cancer, i.e., metastatic castration-resistant prostate…
- Trial name
- NCT06615752
- Testing
- green tea and quercetin + docetaxel
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Charles Drew University of Medicine and Science
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
- Trial name
- NCT05413850
- Testing
- Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only)
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 82 people
- Sponsor
- Blue Earth Therapeutics Ltd
Prostate Cancer
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
The first goal of this study is to learn more about the experience of pain and other symptoms in men being treated for advanced prostate cancer.
- Trial name
- NCT01617174
- Testing
- Webcore telephone survey system
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Castration-resistant Prostate Cancer
The COSMYC Trial (COmbined Suppression of MYC)
This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that…
- Trial name
- NCT06922318
- Testing
- ZEN-3694, Testosterone cypionate, Enzalutamide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, Prostatic Neoplasms
Predictive Factors for Response to Lutetium-177 PSMA Radioligand Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
The goal of this observational study is to learn which factors can predict how well lutetium-177 PSMA therapy works in people with metastatic castration-resistant prostate cancer (mCRPC).
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Neoplasm Metastases
- Trial name
- NCT07863986
- Testing
- [177Lu]Lu-PSMA-617 (Pluvicto, Novartis), 68Ga-PSMA-11 PET/CT, Post-therapy 177Lu-PSMA SPECT/CT dosimetry
- Where
- Lithuania
- Volunteers
- 70 people
- Sponsor
- Lithuanian University of Health Sciences
Metastatic Castration-resistant Prostate Cancer
A Study of FT-7051 in Men With MCRPC
This is a Phase 1, open-label study that will evaluate the safety and tolerability of FT-7051 and determine the recommended Phase 2 dose (RP2D) as well as pharmacokinetics (PK), preliminary anti-tumor activity, and…
- Trial name
- NCT04575766
- Testing
- FT-7051
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Novo Nordisk A/S
Metastatic Prostate Cancer, Prostate Cancer
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
This is an open label, single arm, phase 1b study to determine the safety of combining sequential Prostate-Specific Membrane Antigen (PSMA)-targeted 177Lu-PSMA-617 radionuclide therapy with liver-directed therapy in metastatic…
- Trial name
- NCT07145177
- Testing
- 177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
The aim of the study is to compare in an exploratory fashion the efficacy on progression-free survival of lanreotide in addition to non steroidal anti androgens and LHRH-a in non metastatic castrate resistant prostate cancer…
- Trial name
- POSEIDON (NCT01313273)
- Testing
- Lanreotide, non steroidal anti androgens and LHRH-a, Non steroidal anti androgens and LHRH-a
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Ipsen
Prostate Carcinoma, Castration-resistant Prostate Cancer
Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic
This study compares the biological activity of cabazitaxel (6 cycles) to that of docetaxel (6 cycles) in metastatic castrate-resistant prostate cancer (mCRPC) patients with docetaxel resistant mCRPC defined as ≥5 circulating…
- Conditions
- Prostate Carcinoma, Castration-resistant Prostate Cancer, Circulating Tumor Cells, Chemotherapy
- Trial name
- TACTIK (NCT03101046)
- Testing
- Cabazitaxel, Docetaxel
- Where
- 5 sites in France
- Volunteers
- 40 people
- Sponsor
- UNICANCER
Prostate Cancer
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to demonstrate the safety and effectiveness of abiraterone acetate when co-administered with prednisone in patients with chemo-naive metastatic castration resistant prostate Cancer (mCRPC).
- Trial name
- NCT01591122
- Testing
- Abiraterone acetate and prednisone
- Where
- 22 sites in China, Malaysia and 2 more
- Volunteers
- 313 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00293371
- Testing
- docetaxel, prednisone, vatalanib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Metastatic Castration Resistant Prostate Cancer, mCRPC
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC).
- Conditions
- Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
- Trial name
- NCT07719361
- Testing
- FX-111
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Flare Therapeutics Inc.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
This study will address health authorities' requests to determine whether moderate and severe renal impairment have an impact on the biodistribution, dosimetry and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617)…
- Trial name
- NCT06004661
- Testing
- AAA617, 68Ga-PSMA-11
- Where
- 9 sites in United States, France and 3 more
- Volunteers
- 23 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
The purpose of this research study is to test the safety and possible side effects of Lutetium-177 (177Lu)-Prostate-Specific Membrane Antigen (PSMA)-617 along with niraparib and abiraterone acetate plus prednisone when it is…
- Conditions
- Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Trial name
- LUNAAR (NCT06329830)
- Testing
- 177Lu-PSMA-617, Niraparib abiraterone acetate, Prednisone
- Where
- United States
- Sponsor
- Baptist Health South Florida
Prostate Cancer
Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer
The purpose of this study is to determine whether prostate cancer growth can be slowed in patients who receive Androgel® 1% at 10 gram dose.
- Trial name
- NCT00515112
- Testing
- AndroGel
- Where
- 11 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Chicago
Metastatic Cancer, Prostate Cancer
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as docetaxel, prednisone, and atrasentan work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00134056
- Testing
- atrasentan hydrochloride, docetaxel, prednisone
- Where
- 554 sites in United States
- Volunteers
- 1,038 people
- Sponsor
- SWOG Cancer Research Network